Galcanezumab
Summary
Risk. "The active substance galcanezumab is a protein, the use of which will not alter the concentration or distribution of the substance in the environment. Therefore, galcanezumab is not expected to pose a risk to the environment."
This summary information is taken from the assessment report for Emgality (galcanezumab).
Detailed information
Assessment report
Assessment report for Emgality (galcanezumab) 20 September 2018 EMA/708631/2018.
"The active substance galcanezumab is a protein, the use of which will not alter the concentration or distribution of the substance in the environment. Therefore, galcanezumab is not expected to pose a risk to the environment."
Fass environmental information
Environmental information for galcanezumab is not available on Fass.se (2020-10-06).
Author: Health and Medical Care Administration, Region Stockholm